

Skin Lymphoma

The Illustrated Guide

Lorenzo Cerroni, MD

Director, Dermatopathology Research Center
Medical University of Graz
Graz, Austria

Sixth Edition

WILEY

Contents

Preface, xii

1 Introduction, 1

- Classification of cutaneous lymphomas, 1
- Examination of patients, 2
- Staging investigations, 2
- Surgical techniques, 2
- Histopathology, immunophenotype, and molecular genetics, 4
- Other methods used in the study of cutaneous lymphoid infiltrates, 11
- Lymphoma microenvironment and lymphoma-associated microorganisms, 11
- Pseudomalignancy, premalignancy, and early malignancy, 12

Section 1: Cutaneous NK/T-cell lymphomas and lymphoproliferative disorders

2 The “parapsoriasis”, 17

3 Mycosis fungoides, 26

- Onset of mycosis fungoides or exacerbation of undiagnosed disease under treatment with immunomodulatory agents, 28
- Clinical features, 29
- Extracutaneous involvement, 34
- Association with other diseases, 37
- Histopathology, immunophenotype, and molecular genetics, 39
- Histopathologic differential diagnosis from inflammatory conditions, 61
- Clinical and histopathologic variants, 62

Mycosis fungoides in children and adolescents, 99

Treatment, 100

Prognosis, 111

4 Sézary syndrome, 135

- Onset/progression under systemic therapies for benign inflammatory dermatoses, 137
- Clinical features, 137
- Histopathology, immunophenotype, and molecular genetics, 145
- Treatment, 149
- Prognosis, 151

5 Primary cutaneous CD30⁺ lymphoproliferative disorders, 158

- Lymphomatoid Papulosis, 159
- Cutaneous Anaplastic Large Cell Lymphoma, 180
- “Borderline” Cases, 198
- Intralymphatic CD30⁺ Large T-Cell Lymphoma, 199
- Implant-associated anaplastic large cell lymphoma, 202

6 Subcutaneous panniculitis-like T-cell lymphoma, 211

- Clinical features, 212
- Histopathology, immunophenotype, and molecular genetics, 214
- Differential diagnosis with other cutaneous NK/T-cell lymphomas with prominent involvement of the subcutaneous tissue, 218
- Differential diagnosis with lupus panniculitis, 218
- Treatment, 219
- Prognosis, 223

- 7** Primary cutaneous aggressive epidermotropic CD8⁺ cytotoxic T-Cell lymphoma, 227
 Clinical features, 227
 Histopathology, immunophenotype, and molecular genetics, 227
 Treatment, 233
 Prognosis, 236
- 8** Primary cutaneous γ/δ T-cell lymphoma, 240
 Clinical features, 242
 Histopathology, immunophenotype, and molecular genetics, 243
 Prognosis, 248
- 9** Cutaneous extranodal NK/T-cell lymphoma, nasal type, 254
 Clinical features, 254
 Histopathology, immunophenotype, and molecular genetics, 256
 Treatment, 262
 Prognosis, 263
- 10** Cutaneous peripheral T-cell lymphoma, not otherwise specified (NOS), 266
 Clinical features, 267
 Histopathology, immunophenotype, and molecular genetics, 268
 Treatment, 272
 Prognosis, 272
- 11** Cutaneous CD4⁺ small–medium T-cell lymphoproliferative disorder, 278
 Clinical features, 280
 Histopathology, immunophenotype, and molecular genetics, 281
 Treatment, 284
 Prognosis, 284
 Final considerations, 284
- 12** Primary cutaneous acral CD8⁺ T-cell lymphoproliferative disorder, 287
 Clinical features, 287
 Histopathology, immunophenotype, and molecular genetics, 287
 Treatment, 288
 Prognosis, 288
- 13** Cutaneous adult T-cell leukemia/lymphoma, 291
 Clinical features, 291
 Histopathology, 291
 Immunophenotype, 291
 Molecular genetics, 293
 Treatment, 293
 Prognosis, 293
- 14** Specific cutaneous manifestations of nodal T-follicular helper cell lymphoma, angioimmunoblastic type, and of other nodal T-follicular helper cell lymphomas, 296
 Clinical features, 296
 Histopathology, 296
 Immunophenotype, 299
 Molecular genetics, 299
 Treatment, 299
 Prognosis, 299
- 15** Cutaneous manifestations in Epstein–Barr virus-positive T-cell and NK-cell lymphoid proliferations and lymphomas of childhood, 304
 Severe mosquito bite allergy, 304
 Hydroa-vacciniforme lymphoproliferative disorders, 305
 Classic hydroa vacciniforme, 306
 Systemic hydroa vacciniforme lymphoproliferative disorder, 309
- Section 2: Cutaneous B-cell lymphomas and lymphoproliferative disorders**
- 16** Cutaneous follicle center lymphoma, 317
 Clinical features, 317
 Histopathology, immunophenotype, and molecular genetics, 321
 Differential diagnosis of cutaneous follicle center lymphoma, diffuse type, from cutaneous diffuse large B-cell lymphoma, leg type, 336
 Treatment, 336
 Prognosis, 337

- 17** Primary cutaneous marginal zone lymphoproliferative disorder (primary cutaneous marginal zone lymphoma) and variants, 341
- Cutaneous marginal zone lymphoproliferative disorder, conventional variant, 343
 - Clinical features, 344
 - Histopathology, immunophenotype, and molecular genetics, 345
 - Treatment, 354
 - Prognosis, 355
 - Cutaneous marginal zone lymphoproliferative disorder, lymphoplasmacytic variant, 356
 - Clinical features, 356
 - Histopathology, immunophenotype, and molecular genetics, 356
 - Treatment, 358
 - Prognosis, 358
 - Cutaneous marginal zone lymphoproliferative disorder, plasmacytic variant, 359
 - Clinical features, 359
 - Histopathology, immunophenotype, and molecular genetics, 359
 - Treatment and prognosis, 359
 - Cutaneous marginal zone lymphoproliferative disorder, blastoid variant, 361
 - Clinical features, 361
 - Histopathology, immunophenotype, and molecular genetics, 361
 - Treatment and prognosis, 362
 - Cutaneous amyloidoma, 362
 - Clinical features, 364
 - Histopathology, immunophenotype, and molecular genetics, 364
 - Treatment and prognosis, 364
- 18** Cutaneous diffuse large B-cell lymphoma, leg type, 370
- Clinical features, 371
 - Histopathology, immunophenotype, and molecular genetics, 372
 - Treatment, 380
 - Prognosis, 380
- Primary cutaneous diffuse large B-cell lymphoma, NOS, 381
- 19** Intravascular large cell lymphomas, 387
- Intravascular large B-cell lymphoma, 388
 - Intravascular large NK/T-cell lymphoma, 394
- 20** Other cutaneous B-cell lymphomas, 400
- Cutaneous manifestations of Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma, 400
 - Cutaneous manifestations of mantle cell lymphoma, 403
 - Cutaneous manifestations of extracavitary primary effusion lymphoma, 408
 - Cutaneous manifestations of multiple myeloma, 411
 - Cutaneous manifestations of Burkitt lymphoma, 414
 - Cutaneous lymphomatoid granulomatosis, 416
 - Cutaneous plasmablastic lymphoma, 419
 - Cutaneous T-cell/histiocyte-rich large B-cell lymphoma, 420
 - Cutaneous manifestations of Waldenström macroglobulinemia, 424
- Section 3: Cutaneous lymphomas and lymphoproliferative disorders in the setting of immune deficiency / dysregulation**
- 21** Cutaneous lymphoproliferative disorders and lymphomas in the setting of immune deficiency/dysregulation, 433
- Posttransplant immunodeficiency/dysregulation, 439
 - Human immunodeficiency virus (HIV)-related immune deficiency/dysregulation, 439
 - Cutaneous plasmacytic hyperplasia associated with immune deficiency/dysregulation, 441
 - Cutaneous polymorphic B-cell lymphoproliferative disorder associated with immune deficiency/dysregulation, 443
 - Epstein–Barr virus (EBV)-associated mucocutaneous ulcers, 446
 - Cutaneous manifestations of multicentric Castleman disease, 448

Section 4: Specific cutaneous manifestations of leukemias and of precursor hematologic neoplasms

- 22** Cutaneous manifestations of B-cell chronic lymphocytic leukemia, 455
 - Clinical features, 455
 - Histopathology, immunophenotype, and molecular genetics, 456
 - Treatment and prognosis, 461
 - Progression to diffuse large B-cell lymphoma (Richter syndrome), 464
- 23** Cutaneous manifestations of myelogenous leukemia, 471
 - Acute myeloid leukemia, 472
 - Chronic myelogenous leukemia, 484
 - Myelodysplastic syndromes (myelodysplastic neoplasms), 489
 - Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasms, 492
- 24** Blastic plasmacytoid dendritic cell neoplasm, 495
 - Clinical features, 495
 - Histopathology, immunophenotype, and molecular genetics, 497
 - Treatment, 502
 - Prognosis, 503
- 25** Cutaneous manifestations of other leukemias, 507
 - T-cell prolymphocytic leukemia, 507
 - Aggressive natural killer cell leukemia, 509
 - Specific skin manifestations of other types of leukemia, 510
- 26** Cutaneous lymphoblastic lymphomas, 513
 - Cutaneous B-Lymphoblastic Lymphoma, 513
 - Clinical features, 514
 - Histopathology, immunophenotype, and molecular genetics, 514
 - Differential diagnosis, 516
 - Treatment and prognosis, 517
 - Cutaneous T-Lymphoblastic Lymphoma, 518
 - Clinical features, 518

Histopathology, immunophenotype, and molecular genetics, 519

Treatment and prognosis, 519

Section 5: Cutaneous manifestations of other lymphomas and non-neoplastic cutaneous signs of systemic lymphomas

- 27** Cutaneous manifestations of Hodgkin lymphoma, 527
 - Clinical features, 528
 - Histopathology, immunophenotype, and molecular genetics, 528
 - Treatment and prognosis, 530
 - Primary cutaneous Hodgkin lymphoma, 530
- 28** Cutaneous composite lymphomas, 533
 - Clinical features, 534
 - Histopathology, immunophenotype, and molecular genetics, 534
 - Treatment and prognosis, 538
- 29** Non-neoplastic cutaneous signs of systemic lymphomas, 541

Section 6: Cutaneous lymphomas and lymphoproliferative disorders in children and adolescents

- 30** Cutaneous lymphomas and lymphoproliferative disorders in children and adolescents, 599
 - Mycosis fungoides, 599

Section 7: Pseudolymphomas of the skin

- 31** Pseudolymphomas of the skin, 577
 - Chronic actinic dermatitis (actinic reticuloid), 578
 - Lymphomatoid contact dermatitis, 580
 - Pseudolymphomatous atopic dermatitis and other eczematous dermatoses, 582
 - Non-neoplastic erythroderma in adult patients, 592
 - Solitary idiopathic T/B-cell pseudolymphoma, 598
 - Lichenoid/lymphomatoid keratosis, 600
 - Pityriasis lichenoides, 601

- Lichen aureus/lichenoid pigmented purpuric dermatitis, 605
- Lichen sclerosus, 606
- Vitiligo (inflammatory stage), 609
- Annular lichenoid dermatitis of youth, 609
- Pseudolymphomatous cutaneous infiltrates in human immunodeficiency virus (HIV)-infected patients and in other immune deficiencies, 609
- CD30⁺ T-cell pseudolymphomas, 614
- Persistent nodular arthropod bite reactions and nodular scabies, 616
- Pseudolymphomas in herpes simplex and herpes zoster infections, 620
- Pseudolymphomas associated with lupus erythematosus, 621
- Lymphomatoid drug reactions, 630
- Lymphocytoma cutis, 633
- Pseudolymphomas associated with infections by *Borrelia* species, 635
- Pseudolymphomas at sites of vaccination, 642
- Localized scleroderma/morphea, 647
- Cutaneous IgG4-related disease, 649
- Pseudolymphomas in syphilis, 649
- Cutaneous plasma cell granuloma, 654
- Cutaneous and systemic plasmacytosis, 655
- Angiomatoid pseudolymphoma (T-cell-rich angiomatoid polypoid pseudolymphoma / Acral pseudolymphomatous angiokeratoma in children / Pre-tibial lymphoplasmacytic plaque in children), 655
- Cutaneous extramedullary hematopoiesis, 658
- Histiocytoid cells in Sweet syndrome and other conditions, 659
- Intralymphatic histiocytosis, 661
- Benign intralymphatic proliferation of T-cell lymphoid blasts, 662
- Other “accidental” pseudolymphomas, 667
- 32** Nonlymphoid malignant neoplasms of the skin mimicking histopathologically cutaneous lymphomas (“malignant pseudolymphomas”), 677
- Section 8: The cutaneous “atypical lymphoid proliferation”**
- 33** The cutaneous “atypical lymphoid proliferation”, 687
- Index, 690